Home » Stocks » Vascular Biogenics

Vascular Biogenics Ltd. (VBLT)

Stock Price: $1.23 USD 0.02 (1.65%)
Updated Oct 19, 2020 9:32 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 58.91M
Revenue (ttm) 729,000
Net Income (ttm) -21.78M
Shares Out 47.90M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $1.23
Previous Close $1.21
Change ($) 0.02
Change (%) 1.65%
Day's Open 1.21
Day's Range 1.18 - 1.23
Day's Volume 4,976
52-Week Range 0.90 - 1.64

More Stats

Market Cap 58.91M
Enterprise Value 20.60M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 47.90M
Float 32.30M
EPS (basic) 0.59
EPS (diluted) -0.58
FCF / Share -0.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 539,024
Short Ratio 0.42
Short % of Float 1.67%
Beta 0.89
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 80.81
PB Ratio 1.41
Revenue 729,000
Operating Income -22.26M
Net Income -21.78M
Free Cash Flow -20.04M
Net Cash 38.31M
Net Cash / Share 0.80
Gross Margin 54.73%
Operating Margin -3,052.95%
Profit Margin -2,987.10%
FCF Margin -2,748.83%
ROA -25.32%
ROE -49.48%
ROIC -74.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.85*
(213.01% upside)
Low
2.50
Current: $1.23
High
5.00
Target: 3.85
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue0.560.5913.86-----
Revenue Growth-3.93%-95.78%------
Gross Profit0.400.3513.52-----
Operating Income-20.01-21.21-10.66-16.28-14.87-14.78-15.96-12.47
Net Income-19.46-20.46-10.14-16.00-14.89-17.41-17.37-12.23
Shares Outstanding35.8832.9727.4024.9720.315.631.101.10
Earnings Per Share0.540.620.370.640.733.0915.8211.13
EPS Growth-12.9%67.57%-42.19%-12.33%-76.38%-80.47%42.14%-
Operating Cash Flow-12.70-15.68-3.82-13.41-13.20-13.70-13.13-13.01
Capital Expenditures-0.07-2.23-6.48-0.49-0.09-0.06-0.03-0.16
Free Cash Flow-12.77-17.91-10.30-13.90-13.29-13.76-13.16-13.16
Cash & Equivalents36.5450.4854.7345.2537.1536.7810.8713.96
Total Debt2.940.80----31.04-
Net Cash / Debt33.6049.6954.7345.2537.1536.78-20.1713.96
Assets48.6260.6865.6947.2739.2438.1411.8315.22
Liabilities12.787.599.794.874.233.0435.412.55
Book Value35.8453.0955.9042.4035.0135.10-23.5812.67
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vascular Biogenics Ltd.
Country Israel
Employees 39
CEO Dror Harats

Stock Information

Ticker Symbol VBLT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VBLT
IPO Date October 1, 2014

Description

Vascular Biogenics, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.